Intrinsic sympathomimetic activity: Difference between revisions
Jump to navigation
Jump to search
m Protected "Intrinsic sympathomimetic activity": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
Some beta blockers (e.g. [[oxprenolol]], [[pindolol]], [[penbutolol]] and [[acebutolol]]) exhibit intrinsic sympathomimetic activity (ISA). These agents are capable of exerting low level [[receptor agonist|agonist]] activity at the β-adrenergic receptor while simultaneously acting as a receptor site [[receptor antagonist|antagonist]]. These agents, therefore, may be useful in individuals exhibiting excessive [[bradycardia]] with sustained beta blocker therapy. | Some beta blockers (e.g. [[oxprenolol]], [[pindolol]], [[penbutolol]] and [[acebutolol]]) exhibit intrinsic sympathomimetic activity (ISA). These agents are capable of exerting low level [[receptor agonist|agonist]] activity at the β-adrenergic receptor while simultaneously acting as a receptor site [[receptor antagonist|antagonist]]. These agents, therefore, may be useful in individuals exhibiting excessive [[bradycardia]] with sustained beta blocker therapy. | ||
| Line 12: | Line 12: | ||
<references/> | <references/> | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 16:32, 9 August 2012
| Cardiology Network |
 Discuss Intrinsic sympathomimetic activity further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Some beta blockers (e.g. oxprenolol, pindolol, penbutolol and acebutolol) exhibit intrinsic sympathomimetic activity (ISA). These agents are capable of exerting low level agonist activity at the β-adrenergic receptor while simultaneously acting as a receptor site antagonist. These agents, therefore, may be useful in individuals exhibiting excessive bradycardia with sustained beta blocker therapy.
Agents with ISA are not used in post-myocardial infarction as they have not been demonstrated to be beneficial. They may also be less effective than other beta blockers in the management of angina and tachyarrhythmia.[1]
References
- ↑ Editor Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook.